· Business development
Junshi and Fosun Wanbang sign a Greater China agreement for roconkibart
Junshi announced a licensing agreement with Fosun Wanbang for roconkibart, an antibody targeting IL-17A.
The agreement covers development, regulatory registration, manufacturing and commercialization in Greater China. Fosun Wanbang is a subsidiary of Fosun Pharma.
Read the full company release